Skip to main content
Premium Trial:

Request an Annual Quote

DermTech Inks Coverage Deal for Melanoma Assay

NEW YORK (GenomeWeb) – DermTech announced on Monday that it has secured payor coverage for its pigmented lesion assay (PLA) from CareFirst Blue Cross/Blue Shield and its affiliate CareFirst BlueChoice.

The non-invasive assay is designed to analyze the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions. DermTech said that CareFirst will now cover the test for its 3.4 million members, effective for claims for services performed on or after June 1.

"This is the first contract of the many anticipated for our skin cancer pathology tests executed directly with one of the larger BlueCross Blue/Shield providers," Sarah Dion, vice president of sales and marketing at DermTech, said in a statement. 

About a year ago, DermTech signed an agreement under which Quest Diagnostics-owned dermatopathology services provider Dermpath is helping market the PLA.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.